Glenmede Trust’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.85M | Buy |
54,585
+1,208
| +2% | +$40.2K | 0.01% | 606 |
|
|
2026
Q1 | $1.61M | Buy |
53,377
+44,273
| +486% | +$1.42M | 0.01% | 624 |
|
|
2025
Q4 | $284K | Buy |
+9,104
| New | +$224K | ﹤0.01% | 1166 |
|
|
2020
Q4 | – | Sell |
-2,125
| Closed | -$18K | – | 2150 |
|
|
2020
Q3 | $18K | Buy |
2,125
+41
| +2% | +$434 | ﹤0.01% | 1661 |
|
|
2020
Q2 | $24K | Sell |
2,084
-422
| -17% | -$4.77K | ﹤0.01% | 1526 |
|
|
2020
Q1 | $23K | Hold |
2,506
| – | – | ﹤0.01% | 2022 |
|
|
2019
Q4 | $23K | Sell |
2,506
-1,400
| -36% | -$12.5K | ﹤0.01% | 2022 |
|
|
2019
Q3 | $26K | Sell |
3,906
-1,238
| -24% | -$9.48K | ﹤0.01% | 1922 |
|
|
2019
Q2 | $47K | Sell |
5,144
-12,985
| -72% | -$157K | ﹤0.01% | 1705 |
|
|
2019
Q1 | $284K | Sell |
18,129
-95
| -0.5% | -$1.68K | ﹤0.01% | 1056 |
|
|
2018
Q4 | $280K | Buy |
18,224
+2,676
| +17% | +$54.9K | ﹤0.01% | 1005 |
|
|
2018
Q3 | $334K | Sell |
15,548
-38
| -0.2% | -$882 | ﹤0.01% | 990 |
|
|
2018
Q2 | $379K | Sell |
15,586
-7,083
| -31% | -$144K | ﹤0.01% | 886 |
|
|
2018
Q1 | $429K | Hold |
22,669
| – | – | ﹤0.01% | 954 |
|
|
2017
Q4 | $429K | Sell |
22,669
-2,356
| -9% | -$35.4K | ﹤0.01% | 954 |
|
|
2017
Q3 | $439K | Sell |
25,025
-5,999
| -19% | -$135K | ﹤0.01% | 944 |
|
|
2017
Q2 | $995K | Hold |
31,024
| – | – | ﹤0.01% | 769 |
|
|
2017
Q1 | $995K | Sell |
31,024
-13,943
| -31% | -$476K | ﹤0.01% | 769 |
|
|
2016
Q4 | $1.63M | Sell |
44,967
-1,014
| -2% | -$40.5K | 0.01% | 659 |
|
|
2016
Q3 | $2.11M | Sell |
45,981
-3,476
| -7% | -$181K | 0.01% | 619 |
|
|
2016
Q2 | $2.48M | Sell |
49,457
-81,923
| -62% | -$4.36M | 0.02% | 580 |
|
|
2016
Q1 | $7.03M | Sell |
131,380
-13,592
| -9% | -$798K | 0.05% | 384 |
|
|
2015
Q4 | $9.51M | Buy |
144,972
+26,660
| +23% | +$1.65M | 0.06% | 347 |
|
|
2015
Q3 | $6.68M | Buy |
118,312
+31,142
| +36% | +$2.02M | 0.05% | 375 |
|
|
2015
Q2 | $5.15M | Buy |
87,170
+15,081
| +21% | +$930K | 0.04% | 408 |
|
|
2015
Q1 | $4.49M | Buy |
72,089
+20,444
| +40% | +$1.19M | 0.03% | 447 |
|
|
2014
Q4 | $2.97M | Buy |
51,645
+8,290
| +19% | +$462K | 0.02% | 492 |
|
|
2014
Q3 | $2.33M | Buy |
43,355
+2,642
| +6% | +$140K | 0.02% | 519 |
|
|
2014
Q2 | $2.13M | Buy |
40,713
+664
| +2% | +$33.9K | 0.02% | 538 |
|
|
2014
Q1 | $2.12M | Buy |
40,049
+1,743
| +5% | +$80.6K | 0.02% | 543 |
|
|
2013
Q4 | $1.53M | Sell |
38,306
-22,118
| -37% | -$871K | 0.02% | 576 |
|
|
2013
Q3 | $2.28M | Sell |
60,424
-6,479
| -10% | -$253K | 0.03% | 503 |
|
|
2013
Q2 | $2.62M | Buy |
+66,903
| New | +$2.61M | 0.03% | 455 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Glenmede Trust's TEVA Position: Q2 2026 in Review
Glenmede Trust increased its Teva Pharmaceuticals (TEVA) stake by 2.3% in Q2 2026, buying an estimated $40.2K and bringing the position to 54,585 shares worth $1.85M. The position accounts for 0.01% of the portfolio, ranked #606.
Glenmede Trust first reported a position in TEVA in Q2 2013 and has held it in 33 quarters since. The position peaked at $9.51M in Q4 2015. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Glenmede Trust held 54,585 shares of Teva Pharmaceuticals worth $1.85M as of Q2 2026.
- Glenmede Trust bought 1,208 Teva Pharmaceuticals shares in Q2 2026, an estimated $40.2K.
- Teva Pharmaceuticals made up 0.01% of Glenmede Trust's portfolio in Q2 2026, its #606 holding.
- Glenmede Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
- Glenmede Trust's Teva Pharmaceuticals position peaked at $9.51M in Q4 2015.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.